Samsung Pharmaceutical veers into DNA-sequencing service market

Published: 2012-08-17 06:56:00

Updated: 2012-08-17 06:56:00

Samsung Pharmaceutical Co., which has been struggling to stay the course amid deepening business recession, is trying to find a breakthrough by joining DNA-sequencing service market with a local biopharmaceutical firm.

Samsung said Tuesday that it signed an agreement with Medizen Humancare to ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK